Empowered Patient Podcast

Adrian Mendes, Chief Executive Officer at Perimeter Medical,  has developed a platform that uses AI and optical coherence tormography (OCT) imaging to provide surgeons with real-time visualization of tumor margins during breast cancer surgery.  By scanning while the patient is still in the operating room the platform enables surgeons to identify cancerous cells at the margins and remove addiional tissue, eliminating the need for delayed pathology review and possible additional surgery. This technology benefits all stakeholders- the patients avoid repeat surgery, surgeons see a higher success rate, hospitals optimize operating room utilization, and payers have reduced costs.  Adrian explains, "So fundamentally, the challenge that we see out there in cancer surgery, and specifically in breast cancer surgery, is that there's a very high rate of patients who have to come back in for a second surgery. For breast cancer, it's about one in every four to one in every five patients who go through breast cancer surgery who have to come back again because a surgeon unfortunately wasn't able to remove all the cancer. And so we help them with that." "What we do is we have a product that has an imaging system in it that uses a unique modality type of imaging that has very high resolution. And with that, the surgeons can, in real time, look within the margin of the tumor and inspect it and then make a decision on whether they need to take more tissue right there in that first surgery because they see some cancerous cells in that margin or not." "Fundamentally, the goal of a surgery, a cancer surgery, the way it's judged as being successful or not, is if they're able to remove the tumor and have a few millimeters thick of clean margin, no cancerous cells within that two-millimeter margin, and then that would be considered a successful surgery. And it's very hard to do. And not being able to do that is what leads to that very high re-operation rate." #PerimeterMedical #BreastCancer #Healthcare #ArtificialIntelligence #AIinHealthcare #DigitalHealth #MedTech #CancerCare #MedicalImaging #BreastCancerSurgery #SurgicalOncology #AIinMedicine #MedTech #ORInnovation #HealthcareAI #FDAApproved #PatientOutcomes perimetermed.com  Listen to the podcast here

Adrian Mendes, Chief Executive Officer at Perimeter Medical,  has developed a platform that uses AI and optical coherence tormography (OCT) imaging to provide surgeons with real-time visualization of tumor margins during breast cancer surgery.  By scanning while the patient is still in the operating room the platform enables surgeons to identify cancerous cells at the margins and remove addiional tissue, eliminating the need for delayed pathology review and possible additional surgery. This technology benefits all stakeholders- the patients avoid repeat surgery, surgeons see a higher success rate, hospitals optimize operating room utilization, and payers have reduced costs.  Adrian explains, "So fundamentally, the challenge that we see out there in cancer surgery, and specifically in breast cancer surgery, is that there's a very high rate of patients who have to come back in for a second surgery. For breast cancer, it's about one in every four to one in every five patients who go through breast cancer surgery who have to come back again because a surgeon unfortunately wasn't able to remove all the cancer. And so we help them with that." "What we do is we have a product that has an imaging system in it that uses a unique modality type of imaging that has very high resolution. And with that, the surgeons can, in real time, look within the margin of the tumor and inspect it and then make a decision on whether they need to take more tissue right there in that first surgery because they see some cancerous cells in that margin or not." "Fundamentally, the goal of a surgery, a cancer surgery, the way it's judged as being successful or not, is if they're able to remove the tumor and have a few millimeters thick of clean margin, no cancerous cells within that two-millimeter margin, and then that would be considered a successful surgery. And it's very hard to do. And not being able to do that is what leads to that very high re-operation rate." #PerimeterMedical #BreastCancer #Healthcare #ArtificialIntelligence #AIinHealthcare #DigitalHealth #MedTech #CancerCare #MedicalImaging #BreastCancerSurgery #SurgicalOncology #AIinMedicine #MedTech #ORInnovation #HealthcareAI #FDAApproved #PatientOutcomes perimetermed.com Download the transcript here

Dr. Neil Inhaber, VP and Head of Global Medical Affairs at Takeda,  highlights the complexities of cytomegalovirus (CMV) infection following organ transplantation when a patient's immune system is suppressed. Managing post-transplant CMV is particularly challenging because treatments must balance the risk of organ rejection and the need for immunosuppressive and anti-CMV therapies.  Neil explains, "Takeda has been involved in the development of anti-infectives that target post-transplant cytomegalovirus or CMV infection. And this is an area that really has been a challenge for clinicians for as long as I've been in practice. When I first entered practice 40 years ago, I was taking care of lung transplant patients, and then I joined industry about 20 years ago to focus on the industry side. And this is something that's been present even since I was in practice."   "When you think about cytomegalovirus in general, this is not a problem in the general population because about 50% of the population is infected is a strong word, but certainly is colonized with cytomegalovirus. So, for example, I might be carrying it, and I might be one of those 50%. For me, it's no problem at all because my immune system can keep it under control. If I were in a situation where I would need to have my immune system suppressed following an organ transplantation, that is when there is the possibility for the cytomegalovirus to activate."  #Takeda #Maribavir #TransplantID #CMVAwareness #TransplantMedicine #CMV #InfectiousDisease #OrganTransplant #RealWorldEvidence #TransplantInfectiousDisease #MedicalAffairs #HealthcareInnovation Takeda.com Listen to the podcast here

Dr. Neil Inhaber, VP and Head of Global Medical Affairs at Takeda,  highlights the complexities of cytomegalovirus (CMV) infection following organ transplantation when a patient's immune system is suppressed. Managing post-transplant CMV is particularly challenging because treatments must balance the risk of organ rejection and the need for immunosuppressive and anti-CMV therapies. Neil explains, "Takeda has been involved in the development of anti-infectives that target post-transplant cytomegalovirus or CMV infection. And this is an area that really has been a challenge for clinicians for as long as I've been in practice. When I first entered practice 40 years ago, I was taking care of lung transplant patients, and then I joined industry about 20 years ago to focus on the industry side. And this is something that's been present even since I was in practice."   "When you think about cytomegalovirus in general, this is not a problem in the general population because about 50% of the population is infected is a strong word, but certainly is colonized with cytomegalovirus. So, for example, I might be carrying it, and I might be one of those 50%. For me, it's no problem at all because my immune system can keep it under control. If I were in a situation where I would need to have my immune system suppressed following an organ transplantation, that is when there is the possibility for the cytomegalovirus to activate."  #Takeda #Maribavir #TransplantID #CMVAwareness #TransplantMedicine #CMV #InfectiousDisease #OrganTransplant #RealWorldEvidence #TransplantInfectiousDisease #MedicalAffairs #HealthcareInnovation Takeda.com Download the transcript here

Dr. Craig Tanio, Co-Founder of Rezilir Health,  is taking a precision medicine approach to cognitive decline that combines objective performance metrics, identification of root causes, and practical interventions to achieve measurable improvements. This strategy addresses fundamentals including diet, exercise, sleep, cognitive engagement and stress management while looking at underlying drivers such as chronic infections, inflamation, and environmental factors. Craig points out that the healthcare system is gradually recognizing the value of a preventative multimodal approach to the decline in brain health and the value of early diagnosis of cognitive decline, the integration of lifestyle modifications, along with targeted medical interventions. Craig explains, "With cognitive health, the fundamental approach is really around precision medicine. We're looking to help our patients find practical answers to improving cognitive decline by getting A, objective metrics of how their performance is today. B, understanding some of the root causes that can drive cognitive decline, and again, measuring those appropriately. And then C, coming up with a practical strategy in which they can see movement in objective and subjective markers within six months."   "We see three main types of patients. I think we see a group of patients who might have subjective cognitive impairment, or they're seeking aggressive prevention, usually because a parent or close relative has Alzheimer's or cognitive decline and they're very motivated to address it. B, there might be somebody who comes in with mild cognitive impairment and is experiencing symptoms, but let's say their MOCA, their Montreal Cognitive Assessment, is in the low 20s, so they have mild cognitive impairment but not significant impairment of activities of daily living. And then the third is when the disease has progressed more readily and is in the advanced stage beyond mild dementia." #RezilirHealth #RezilirWay #PrecisionMedicine #BrainHealth #EarlyDetection #RootCause #CognitivHealth #Dementia #AlzheimersAwareness #Neurology #LongevityMedicine #HealthSpan #PreventiveMedicine #IntegrativeMedicine #HealthcareInnovation rezilirhealth.com  Listen to the podcast here

Dr. Craig Tanio, Co-Founder of Rezilir Health,  is taking a precision medicine approach to cognitive decline that combines objective performance metrics, identification of root causes, and practical interventions to achieve measurable improvements. This strategy addresses fundamentals including diet, exercise, sleep, cognitive engagement and stress management while looking at underlying drivers such as chronic infections, inflamation, and environmental factors. Craig points out that the healthcare system is gradually recognizing the value of a preventative multimodal approach to the decline in brain health and the value of early diagnosis of cognitive decline, the integration of lifestyle modifications, along with targeted medical interventions. Craig explains, "With cognitive health, the fundamental approach is really around precision medicine. We're looking to help our patients find practical answers to improving cognitive decline by getting A, objective metrics of how their performance is today. B, understanding some of the root causes that can drive cognitive decline, and again, measuring those appropriately. And then C, coming up with a practical strategy in which they can see movement in objective and subjective markers within six months."   "We see three main types of patients. I think we see a group of patients who might have subjective cognitive impairment, or they're seeking aggressive prevention, usually because a parent or close relative has Alzheimer's or cognitive decline and they're very motivated to address it. B, there might be somebody who comes in with mild cognitive impairment and is experiencing symptoms, but let's say their MOCA, their Montreal Cognitive Assessment, is in the low 20s, so they have mild cognitive impairment but not significant impairment of activities of daily living. And then the third is when the disease has progressed more readily and is in the advanced stage beyond mild dementia." #RezilirHealth #RezilirWay #PrecisionMedicine #BrainHealth #EarlyDetection #RootCause #CognitivHealth #Dementia #AlzheimersAwareness #Neurology #LongevityMedicine #HealthSpan #PreventiveMedicine #IntegrativeMedicine #HealthcareInnovation rezilirhealth.com Download the transcript here

Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, discusses the company's virus-based approach for treating multiple tumor types. Their lead therapy is an oral drug and an engineered adenovirus injected into tumors to deliver a gene that educates the patient's immune cells to recognize and eliminate cancer cells throughout the body. Unlike personalized tumor vaccine approaches, this drug is an off-the-shelf medicine that generates an individualized anti-tumor immune response and is showing encouraging data in trials in pancreatic cancer, brain cancer, ovarian cancer, and prostate cancer. Paul Peter explains, "Our mission is really to improve patients' lives, whether this is about patients with early localized prostate cancer, for example, who want to live without cancer, or patients at the other side of the spectrum. For example, patients with metastatic, progressive non-small cell lung cancer, a form of lung cancer, who have run out of options, where we try to extend their life with a good quality of life. So basically, we want to improve patients' clinical outcomes." "We have two investigational medicines that are both engineered viruses. So we try to change the viruses so they do something useful and good for the health of patients. And our lead asset, our lead medicine that's under development, is called aglatimagene. And it's an engineered adenovirus. So it's an adenovirus that cannot replicate, cannot make you sick, but we use it to deliver a gene to the tumor by injecting it into the tumor. And viruses are very good at transporting genes. We hijack that mechanism to get the beneficial effect. And ultimately, we combine aglatimagene with a tablet. So tablets that are taken orally for two weeks are activated under the influence of the virus in the tumor. And that will ultimately lead to the education of the patient's own immune cells in such a way that these immune cells start to recognize and eliminate the tumor cells throughout the body." #CandelTherapeutics $CADL #Oncology #Biotech #ClinicalTrials #ProstateCancer #LungCancer #SolidTumors #OncologyInnovation #Immunotherapy #CancerResearch #Immunooncology #ViralImmunotherapy Candeltx.com Listen to the podcast here 

Dr. Paul Peter Tak, President and CEO of Candel Therapeutics, discusses the company's virus-based approach for treating multiple tumor types. Their lead therapy is an oral drug and an engineered adenovirus injected into tumors to deliver a gene that educates the patient's immune cells to recognize and eliminate cancer cells throughout the body. Unlike personalized tumor vaccine approaches, this drug is an off-the-shelf medicine that generates an individualized anti-tumor immune response and is showing encouraging data in trials in pancreatic cancer, brain cancer, ovarian cancer, and prostate cancer. Paul Peter explains, "Our mission is really to improve patients' lives, whether this is about patients with early localized prostate cancer, for example, who want to live without cancer, or patients at the other side of the spectrum. For example, patients with metastatic, progressive non-small cell lung cancer, a form of lung cancer, who have run out of options, where we try to extend their life with a good quality of life. So basically, we want to improve patients' clinical outcomes." "We have two investigational medicines that are both engineered viruses. So we try to change the viruses so they do something useful and good for the health of patients. And our lead asset, our lead medicine that's under development, is called aglatimagene. And it's an engineered adenovirus. So it's an adenovirus that cannot replicate, cannot make you sick, but we use it to deliver a gene to the tumor by injecting it into the tumor. And viruses are very good at transporting genes. We hijack that mechanism to get the beneficial effect. And ultimately, we combine aglatimagene with a tablet. So tablets that are taken orally for two weeks are activated under the influence of the virus in the tumor. And that will ultimately lead to the education of the patient's own immune cells in such a way that these immune cells start to recognize and eliminate the tumor cells throughout the body." #CandelTherapeutics $CADL #Oncology #Biotech #ClinicalTrials #ProstateCancer #LungCancer #SolidTumors #OncologyInnovation #Immunotherapy #CancerResearch #Immunooncology #ViralImmunotherapy Candeltx.com Download the transcript here 

Al Gianchetti, CEO of Nuevocor,  discusses genetic cardiomyopathies, an underdiagnosed condition that might explain multigenerational heart failure. Current treatments include beta blockers, pacemakers, and heart transplants but do not alter the course of the disease.  Because of multiple gene mutations, Nuevocor is developing a precision therapy for LMNA-related cardiomyopathy based on mechanobiology that prevents cardiac cell death using a method different from gene replacement and gene editing. Al explains, "We're focused on genetic cardiomyopathies, and our lead drug, NVC001 in particular, is focusing first on LMNA cardiomyopathy, and LMNA is a specific gene mutation. We're focusing on LMNA-related cardiomyopathy for several reasons. First of all, it's one of the most severe forms of genetic cardiomyopathy, with a very poor prognosis for patients and their families who have the genetic mutation."   "The second reason is that although it's a rare disease, it affects a fairly large number of people. For example, about 50,000 people in the United States are estimated to have LMNA-related cardiomyopathy. The third reason is that this disease is not amenable to gene replacement strategies where you're replacing the defective gene. The size of the trans gene that's required doesn't make it amenable to current gene therapy viral vectors. Finally, because there are multiple gene mutations, it's not amenable to gene editing." #Nuevocor #DrugDiscovery #Innovation #Biotech #Cardiology #GeneTherapy #GeneticCardiomyopathy #HeartFailure #LMNACardiomyopathy #PrecisionMedicine #RareDisease #ClinicalTrials nuevocor.com Listen to the podcast here

Al Gianchetti, CEO of Nuevocor,  discusses genetic cardiomyopathies, an underdiagnosed condition that might explain multigenerational heart failure. Current treatments include beta blockers, pacemakers, and heart transplants but do not alter the course of the disease.  Because of multiple gene mutations, Nuevocor is developing a precision therapy for LMNA-related cardiomyopathy based on mechanobiology that prevents cardiac cell death using a method different from gene replacement and gene editing. Al explains, "We're focused on genetic cardiomyopathies, and our lead drug, NVC001 in particular, is focusing first on LMNA cardiomyopathy, and LMNA is a specific gene mutation. We're focusing on LMNA-related cardiomyopathy for several reasons. First of all, it's one of the most severe forms of genetic cardiomyopathy, with a very poor prognosis for patients and their families who have the genetic mutation."   "The second reason is that although it's a rare disease, it affects a fairly large number of people. For example, about 50,000 people in the United States are estimated to have LMNA-related cardiomyopathy. The third reason is that this disease is not amenable to gene replacement strategies where you're replacing the defective gene. The size of the trans gene that's required doesn't make it amenable to current gene therapy viral vectors. Finally, because there are multiple gene mutations, it's not amenable to gene editing." #Nuevocor #DrugDiscovery #Innovation #Biotech #Cardiology #GeneTherapy #GeneticCardiomyopathy #HeartFailure #LMNACardiomyopathy #PrecisionMedicine #RareDisease #ClinicalTrials nuevocor.com Download the transcript here

Rakshith Yashvanth, Senior Product Manager, Advanced Analytics & AI at ZeOmega, emphasizes that effective AI implementation in clinical settings requires comprehensive data across clinical, social, utilization, and behavioral elements, not cherry-picked variables. Real-world data indicates that traditional social determinants of health often miss critical behavioral patterns and healthcare engagement. Rakshith points out that AI must be positioned as a probabilistic tool that supports clinical decision-making rather than replacing clinical judgment, with a mechanism that lets clinicians provide feedback to improve model alignment with clinical reality.     Rakshith explains, "ZeOmega focuses more on the population health technology space. Our clients usually are risk-bearing organizations. We have health plans that cover a wide range of populations, including Medicaid, Medicare, commercial, ACOs, and other MSOs and similar entities. So we primarily focus on providing tools to these organizations so they can measure risk, manage risk, and manage their members' overall health and well-being."    "AI is definitely a new technology. It has immense power and capability to go through millions, if not billions, of data points and look for patterns that have traditionally not been baked into clinical training or clinical intuition, or were treated as edge cases. So when it comes to organizations experimenting with and adopting AI right now, the knee-jerk reaction or tendency is to try to take what they have already been doing, which is a lot of these deterministic models based on clinical intuition. They try to map that onto AI, almost trying to evolve these deterministic rule sets or workflows into the AI domain. And this is not a great strategy because, one, we're not really using the true power of AI, which can comb through a lot of data, find things, and handle a lot of complexity." #ZeOmega #PopulationHealth #HealthcareAI #SocialDeterminantsOfHealth #OpioidCrisis #HealthEquity #Medicaid #DigitalHealth #ClinicalAnalytics #AIinHealthcare #HealthcareInnovation #HealthcareAI #RiskStratification #ValueBasedCare #HealthIT ZeOmega.com Listen to the podcast here

Rakshith Yashvanth, Senior Product Manager, Advanced Analytics & AI at ZeOmega, emphasizes that effective AI implementation in clinical settings requires comprehensive data across clinical, social, utilization, and behavioral elements, not cherry-picked variables. Real-world data indicates that traditional social determinants of health often miss critical behavioral patterns and healthcare engagement. Rakshith points out that AI must be positioned as a probabilistic tool that supports clinical decision-making rather than replacing clinical judgment, with a mechanism that lets clinicians provide feedback to improve model alignment with clinical reality.     Rakshith explains, "ZeOmega focuses more on the population health technology space. Our clients usually are risk-bearing organizations. We have health plans that cover a wide range of populations, including Medicaid, Medicare, commercial, ACOs, and other MSOs and similar entities. So we primarily focus on providing tools to these organizations so they can measure risk, manage risk, and manage their members' overall health and well-being."    "AI is definitely a new technology. It has immense power and capability to go through millions, if not billions, of data points and look for patterns that have traditionally not been baked into clinical training or clinical intuition, or were treated as edge cases. So when it comes to organizations experimenting with and adopting AI right now, the knee-jerk reaction or tendency is to try to take what they have already been doing, which is a lot of these deterministic models based on clinical intuition. They try to map that onto AI, almost trying to evolve these deterministic rule sets or workflows into the AI domain. And this is not a great strategy because, one, we're not really using the true power of AI, which can comb through a lot of data, find things, and handle a lot of complexity." #ZeOmega #PopulationHealth #HealthcareAI #SocialDeterminantsOfHealth #OpioidCrisis #HealthEquity #Medicaid #DigitalHealth #ClinicalAnalytics #AIinHealthcare #HealthcareInnovation #HealthcareAI #RiskStratification #ValueBasedCare #HealthIT ZeOmega.com Download the transcript here

Dr. Seth Lederman, CEO and Co-Founder of Tonix,  describes the company's focus on chronic, debilitating, and underserved medical conditions that have been overlooked.  Fibromyalgia, a common chronic pain condition, is a prime focus, and Seth explains how recognition of this neurological condition rooted in the central nervous system has evolved. Additional research is being conducted on a Lyme disease prophylactic, kidney transplant rejection prevention, and targeting depression by improving sleep quality. Seth explains, "The condition we were founded on, which we've worked on for more than 15 years since the company's founding, is fibromyalgia. It's a common chronic pain condition. One of the things I like about fibromyalgia is that it was a paradox described more than 50 years ago by the brilliant physician-scientist Harvey Moldofsky. He noted that if you speak to rheumatologists about fibromyalgia, half of them say they never see it, and the other half say it's one of the most common conditions they see and treat." "Fibromyalgia commonly affects women more than men. It's about two-thirds women by epidemiology, but in practice, in terms of the number of treated patients, it's more than 90% women. And no one understands why women are more sensitive or more susceptible to fibromyalgia than men, but it comes on. A typical patient is about 50 years old and has had it for about 10 years, but fibromyalgia is now recognized to affect people all the way back into pediatric populations and through the elderly." #TonixPharma #Fibromyalgia #LymeDisease #ChronicPain #Biotech #DrugDiscovery #MedEd #HealthcareInnovation #AutoimmuneDisease #ClinicalTrials tonixpharma.com  Listen to the podcast here

Dr. Seth Lederman, CEO and Co-Founder of Tonix,  describes the company's focus on chronic, debilitating, and underserved medical conditions that have been overlooked.  Fibromyalgia, a common chronic pain condition, is a prime focus, and Seth explains how recognition of this neurological condition rooted in the central nervous system has evolved. Additional research is being conducted on a Lyme disease prophylactic, kidney transplant rejection prevention, and targeting depression by improving sleep quality. Seth explains, "The condition we were founded on, which we've worked on for more than 15 years since the company's founding, is fibromyalgia. It's a common chronic pain condition. One of the things I like about fibromyalgia is that it was a paradox described more than 50 years ago by the brilliant physician-scientist Harvey Moldofsky. He noted that if you speak to rheumatologists about fibromyalgia, half of them say they never see it, and the other half say it's one of the most common conditions they see and treat." "Fibromyalgia commonly affects women more than men. It's about two-thirds women by epidemiology, but in practice, in terms of the number of treated patients, it's more than 90% women. And no one understands why women are more sensitive or more susceptible to fibromyalgia than men, but it comes on. A typical patient is about 50 years old and has had it for about 10 years, but fibromyalgia is now recognized to affect people all the way back into pediatric populations and through the elderly." #TonixPharma #Fibromyalgia #LymeDisease #ChronicPain #Biotech #DrugDiscovery #MedEd #HealthcareInnovation #AutoimmuneDisease #ClinicalTrials tonixpharma.com Download the transcript here

Dr. Mike Han, Chief Medical Officer at Ambience Healthcare, describes their AI-powered platform that, with consent, transcribes physician-patient conversations and then uses AI to create comprehensive documentation, including suggested diagnoses and coding recommendations.  By automating documentation and integrating into existing electronic health record systems, the platform enables clinicians to focus on the patient interaction rather than keyboard entry.  The technology targets multiple pain points simultaneously: coding accuracy, documentation of a patient visit, and patient engagement, while reducing downstream errors and payment delays.  Mike explains, "So Ambient Clinical Documentation is a tool that we provide to physicians and APPs. The physician or advanced practice practitioner asks the patient for consent to record the conversation. So the entire conversation is recorded and then transcribed. After it's transcribed, our artificial intelligence platform creates a progress note out of that transcription. Progress notes are broken into several different sections: a subjective section, which is the patient narrative, an objective section, which generally includes vital signs, physical examination, and labs, and then an assessment and plan."   "Furthermore, our tool also suggests diagnoses that the physician can select, as well as coding recommendations to help the physician identify a level of service or medical decision-making complexity surrounding the medical decision-making. And so it really does reduce the physician's cognitive burden during the visit. And what we've seen is that this tool allows the physician to focus on the patient as opposed to the keyboard or the monitor." #Ambience #AmbienceHealthcare #AmbientAI #ClinicalDocumentation #HealthcareAI #PhysicianBurnout #HealthIT #MedicalCoding #PatientCare #AIinHealthcare #DigitalHealth #HealthTech #ClinicianExperience #PatientExperience ambiencehealthcare.com Listen to the podcast here

Dr. Mike Han, Chief Medical Officer at Ambience Healthcare, describes their AI-powered platform that, with consent, transcribes physician-patient conversations and then uses AI to create comprehensive documentation, including suggested diagnoses and coding recommendations.  By automating documentation and integrating into existing electronic health record systems, the platform enables clinicians to focus on the patient interaction rather than keyboard entry.  The technology targets multiple pain points simultaneously: coding accuracy, documentation of a patient visit, and patient engagement, while reducing downstream errors and payment delays.  Mike explains, "So Ambient Clinical Documentation is a tool that we provide to physicians and APPs. The physician or advanced practice practitioner asks the patient for consent to record the conversation. So the entire conversation is recorded and then transcribed. After it's transcribed, our artificial intelligence platform creates a progress note out of that transcription. Progress notes are broken into several different sections: a subjective section, which is the patient narrative, an objective section, which generally includes vital signs, physical examination, and labs, and then an assessment and plan."   "Furthermore, our tool also suggests diagnoses that the physician can select, as well as coding recommendations to help the physician identify a level of service or medical decision-making complexity surrounding the medical decision-making. And so it really does reduce the physician's cognitive burden during the visit. And what we've seen is that this tool allows the physician to focus on the patient as opposed to the keyboard or the monitor." #Ambience #AmbienceHealthcare #AmbientAI #ClinicalDocumentation #HealthcareAI #PhysicianBurnout #HealthIT #MedicalCoding #PatientCare #AIinHealthcare #DigitalHealth #HealthTech #ClinicianExperience #PatientExperience ambiencehealthcare.com Download the transcript here

Dr. Ramon Velazquez, neuroscientist and Scientific Advisor at Mind Lab Pro, discusses the relevance of cognitive endurance to healthy aging and the need to maintain cognitive engagement.  Ramon addresses the dual challenge of modern life, where chronic stress and cognitive overstimulation can impair performance, while insufficient mental challenge also leads to decline. Topics include strategies for brain health, recent neuroscience advances in understanding how the brain can generate new neurons as we age, and the value of exercise, proper nutrition, and cognitive challenges.   Ramon explains, "So cognitive endurance, the way that I think about it, is really the ability to sustain, for example, attention, mental effort, effective thinking over really extended periods of time without a significant decline in performance. So what I think about as an analogy is, if you're an athlete and you are running a marathon, being able to keep up that pace requires endurance. And you can think about that when we're talking about cognitive endurance more in relation to what the brain needs to do in order to achieve that. And why is it becoming more and more important or relevant is the fact that we are starting to really identify ways in which you can improve your cognitive endurance through a variety of different lifestyle factors."   "We can measure this through exams given to an individual, but for the most part, it's really going to be self-report. How does an individual report how they feel after engaging in these mental effort activities? And again, there are various tasks individuals can do that tap into their ability to perform well on a variety of cognitive tasks. But cognitive endurance itself can be tricky to assess because it's going to be, as I mentioned, really self-report: how one feels after engaging in these types of specific mental activities." #MindLabPro #CognitiveEndurance #BrainHealth #HealthcareLeadership #ClinicalWellness #Nootropics #NeuroscienceInPractice #PhysicianWellbeing #MentalPerformance #PreventativeMedicine  mindlabpro.com Listen to the podcast here

Dr. Ramon Velazquez, neuroscientist and Scientific Advisor at Mind Lab Pro, discusses the relevance of cognitive endurance to healthy aging and the need to maintain cognitive engagement.  Ramon addresses the dual challenge of modern life, where chronic stress and cognitive overstimulation can impair performance, while insufficient mental challenge also leads to decline. Topics include strategies for brain health, recent neuroscience advances in understanding how the brain can generate new neurons as we age, and the value of exercise, proper nutrition, and cognitive challenges.   Ramon explains, "So cognitive endurance, the way that I think about it, is really the ability to sustain, for example, attention, mental effort, effective thinking over really extended periods of time without a significant decline in performance. So what I think about as an analogy is, if you're an athlete and you are running a marathon, being able to keep up that pace requires endurance. And you can think about that when we're talking about cognitive endurance more in relation to what the brain needs to do in order to achieve that. And why is it becoming more and more important or relevant is the fact that we are starting to really identify ways in which you can improve your cognitive endurance through a variety of different lifestyle factors."   "We can measure this through exams given to an individual, but for the most part, it's really going to be self-report. How does an individual report how they feel after engaging in these mental effort activities? And again, there are various tasks individuals can do that tap into their ability to perform well on a variety of cognitive tasks. But cognitive endurance itself can be tricky to assess because it's going to be, as I mentioned, really self-report: how one feels after engaging in these types of specific mental activities." #MindLabPro #CognitiveEndurance #BrainHealth #HealthcareLeadership #ClinicalWellness #Nootropics #NeuroscienceInPractice #PhysicianWellbeing #MentalPerformance #PreventativeMedicine  mindlabpro.com Download the transcript here

Suzanne Cogan, President and Chief Customer Officer at WebPT, addresses critical challenges the physical therapy and rehabiliation industry face and the opportunities to use AI to automate administrative tasks and enhance their patients' experiences. Solutions include patient activity tracking, scheduling, billing, insurance claims management ,and monitoring prior authorizations and renewals. The innovations aim to improve patient outcomes, reduce administrative burden, improve financial managment and provide real-time compliance to ensure claims meet payer requirements before submision. Suzanne explains, "WebPT has supported physical therapy, but also occupational therapy, speech-language pathology, and chiropractic, so in combination rehab therapy. We've supported that industry since 2008 in a variety of ways. So essentially, the software that they need to run the business, from scheduling to documenting visits with patients to billing patients and the insurance companies, collecting on those claims, and marketing the practice, to reactivating former patients."   "More and more, we are getting into the realm of leveraging AI to provide more automation and even autonomous action to further improve efficiencies at the PT practice and realize our mission, which has always been empowering rehab therapy professionals to achieve greatness in practice."   "The reimbursement rates have always been on the low side compared to other healthcare professionals. They're not exactly increasing, as really anyone in healthcare can attest, in the last few years. The friction caused by increasing denials and prior auth challenges, and health insurance companies adjudicating claims with AI, continues to be a problem." #WebPT #PhysicalTherapy #RehabTherapy #HealthcareAI #OccupationalTherapy #HealthcareInnovation #PriorAuthorization #PatientCare #HealthTech webpt.com Listen to the podcast here

Suzanne Cogan, President and Chief Customer Officer at WebPT, addresses critical challenges the physical therapy and rehabiliation industry face and the opportunities to use AI to automate administrative tasks and enhance their patients' experiences. Solutions include patient activity tracking, scheduling, billing, insurance claims management ,and monitoring prior authorizations and renewals. The innovations aim to improve patient outcomes, reduce administrative burden, improve financial managment and provide real-time compliance to ensure claims meet payer requirements before submision. Suzanne explains, "WebPT has supported physical therapy, but also occupational therapy, speech-language pathology, and chiropractic, so in combination rehab therapy. We've supported that industry since 2008 in a variety of ways. So essentially, the software that they need to run the business, from scheduling to documenting visits with patients to billing patients and the insurance companies, collecting on those claims, and marketing the practice, to reactivating former patients."   "More and more, we are getting into the realm of leveraging AI to provide more automation and even autonomous action to further improve efficiencies at the PT practice and realize our mission, which has always been empowering rehab therapy professionals to achieve greatness in practice."   "The reimbursement rates have always been on the low side compared to other healthcare professionals. They're not exactly increasing, as really anyone in healthcare can attest, in the last few years. The friction caused by increasing denials and prior auth challenges, and health insurance companies adjudicating claims with AI, continues to be a problem." #WebPT #PhysicalTherapy #RehabTherapy #HealthcareAI #OccupationalTherapy #HealthcareInnovation #PriorAuthorization #PatientCare #HealthTech webpt.com Download the transcript here

Eileen Heffernan, CEO and Co-Founder of Celltaxis, highlights that lymphedema is the most common lymphatic disorder and is a progressive chronic condition characterized by inflammation, fat deposition, and infections.  Currently there are no disease-modifying treatments available, requiring patients to rely on compression garments and manual therapy.  Celltaxis is developing a therapy that targets immune modulation rather than broad immunosuppression and enables lymphatic vessel repair, a potential paradigm shift from symptom management to disease modification. Eileen explains, "The lymphatic system touches every system in the human body and drains extra fluid filled with waste and signs of infection and so forth, drains all of that and brings it back to the vascular system. We at Celtaxis are treating lymphedema, which is the most common lymphatic disorder. It's a life-altering, progressive, chronic disorder initiated by lymphatic vessel failure and causes fluid stasis, inflammation, fat deposition, skin thickening, and infections. In later stages, quite a lot of fibrosis. This results in significant changes to limb volumes and restriction of motion and activities. And there are approximately 10 million people in the United States with lymphedema and no therapies available." "Well, there's been a lack of understanding about how important the lymphatic system is. As recently as 2010 is really when the mindset about how important the lymphatic system is changed, and that's not all that long ago. Previously, we all learned in grade school and so forth that the heart pumped, arteries distributed, and the veins returned. And that's how fluid moved throughout your body. Well, now we know that the veins really don't return much of the fluid. It is the lymphatics that really return all of the fluid. So in this way, the lymphatic system is really a central part of the circulatory system. And when you think of all the lymph nodes all along the lymphatic system that act as sentries looking at the fluid as it passes through the lymph nodes on its way back to the vascular system, the lymph nodes are filtering that lymphatic fluid, looking for signs of infection and really act as the sentries and notify the immune system to mount a response." #Celltaxis #LymphaticDisorders #Lymphatics #Lipedema #Cancer #Obesity #Lymphedema #RareDiseases #ClinicalTrials #Oncology #BreastCancerSurvivors #Immunology #HealthcareInnovation #MedicalResearch celltaxis.com Listen to the podcast here

Eileen Heffernan, CEO and Co-Founder of Celltaxis, highlights that lymphedema is the most common lymphatic disorder and is a progressive chronic condition characterized by inflammation, fat deposition, and infections.  Currently there are no disease-modifying treatments available, requiring patients to rely on compression garments and manual therapy.  Celltaxis is developing a therapy that targets immune modulation rather than broad immunosuppression and enables lymphatic vessel repair, a potential paradigm shift from symptom management to disease modification. Eileen explains, "The lymphatic system touches every system in the human body and drains extra fluid filled with waste and signs of infection and so forth, drains all of that and brings it back to the vascular system. We at Celtaxis are treating lymphedema, which is the most common lymphatic disorder. It's a life-altering, progressive, chronic disorder initiated by lymphatic vessel failure and causes fluid stasis, inflammation, fat deposition, skin thickening, and infections. In later stages, quite a lot of fibrosis. This results in significant changes to limb volumes and restriction of motion and activities. And there are approximately 10 million people in the United States with lymphedema and no therapies available." "Well, there's been a lack of understanding about how important the lymphatic system is. As recently as 2010 is really when the mindset about how important the lymphatic system is changed, and that's not all that long ago. Previously, we all learned in grade school and so forth that the heart pumped, arteries distributed, and the veins returned. And that's how fluid moved throughout your body. Well, now we know that the veins really don't return much of the fluid. It is the lymphatics that really return all of the fluid. So in this way, the lymphatic system is really a central part of the circulatory system. And when you think of all the lymph nodes all along the lymphatic system that act as sentries looking at the fluid as it passes through the lymph nodes on its way back to the vascular system, the lymph nodes are filtering that lymphatic fluid, looking for signs of infection and really act as the sentries and notify the immune system to mount a response." #Celltaxis #LymphaticDisorders #Lymphatics #Lipedema #Cancer #Obesity #Lymphedema #RareDiseases #ClinicalTrials #Oncology #BreastCancerSurvivors #Immunology #HealthcareInnovation #MedicalResearch celltaxis.com Download the transcript here

Samuel Reich, Chief Executive Officer at SAB Bio, is developing a fully human antibody therapy designed to transform type 1 diabetes treatment by preserving patients' beta cells and their ability to produce insulin, rather than just managing symptoms with insulin and glucose monitoring. The drug is produced using the company's bovine platform which uses genetically modified cows to generate human immunoglobulins offering a safer more scalable alternative to rabbit-derived therapies. If successful, this approach could represent a functional cure, potentially transforming type 1 diabetes from a disease requiring daily insulin management to one requiring only periodic infusions. Samuel explains, "Our mission at SAB Bio is to transform what it means to get a type 1 diabetes diagnosis by changing the course of the disease, and not just treating the symptoms, with our new medicine, which is called SAB-142. Why type 1 diabetes? It's a major global unmet medical need that has largely been underserved in research until recently."  "Insulin and glucose monitoring are the standard of care, but they don't treat the disease. They don't treat the patient's illness. They just manage the symptoms and allow the patient to survive. So, they're essential, but they're not helping the patient be healthier or manage the disease process. Our mission is to treat the disease causing type 1 diabetes by saving the patient's beta cells and saving the patient's ability to make their own insulin. And exogenous insulin is no substitute for the patient's own ability to make insulin." "So we have a platform at SAB called the TcBovine, which is a transchromosomal bovine. And these are cows that are healthy and happy cows that look like normal dairy cows, but the cows make human IgG, or human antibodies, instead of cow IgG. And we vaccinate our cows with human thymocytes and purify the IgG from the cow plasma. And our drug is a fully human immunoglobulin, which targets human thymocytes. So, it does what the rabbit drug does, thymoglobulin, but it's human and can be given more safely without making the patient sick, and can be given for the life of the patient to continue to preserve their beta cells for the long term." #SABBio #Type1Diabetes #TD1 #JDRF#Immunology #ClinicalResearch #Endocrinology #AutoimmuneDisease #MedicalInnovation #BetaCells #T1D #HealthcareInnovation #ClinicalTrials sab.bio  Listen to the podcast here

Samuel Reich, Chief Executive Officer at SAB Bio, is developing a fully human antibody therapy designed to transform type 1 diabetes treatment by preserving patients' beta cells and their ability to produce insulin, rather than just managing symptoms with insulin and glucose monitoring. The drug is produced using the company's bovine platform which uses genetically modified cows to generate human immunoglobulins offering a safer more scalable alternative to rabbit-derived therapies. If successful, this approach could represent a functional cure, potentially transforming type 1 diabetes from a disease requiring daily insulin management to one requiring only periodic infusions. Samuel explains, "Our mission at SAB Bio is to transform what it means to get a type 1 diabetes diagnosis by changing the course of the disease, and not just treating the symptoms, with our new medicine, which is called SAB-142. Why type 1 diabetes? It's a major global unmet medical need that has largely been underserved in research until recently."  "Insulin and glucose monitoring are the standard of care, but they don't treat the disease. They don't treat the patient's illness. They just manage the symptoms and allow the patient to survive. So, they're essential, but they're not helping the patient be healthier or manage the disease process. Our mission is to treat the disease causing type 1 diabetes by saving the patient's beta cells and saving the patient's ability to make their own insulin. And exogenous insulin is no substitute for the patient's own ability to make insulin." "So we have a platform at SAB called the TcBovine, which is a transchromosomal bovine. And these are cows that are healthy and happy cows that look like normal dairy cows, but the cows make human IgG, or human antibodies, instead of cow IgG. And we vaccinate our cows with human thymocytes and purify the IgG from the cow plasma. And our drug is a fully human immunoglobulin, which targets human thymocytes. So, it does what the rabbit drug does, thymoglobulin, but it's human and can be given more safely without making the patient sick, and can be given for the life of the patient to continue to preserve their beta cells for the long term." #SABBio #Type1Diabetes #TD1 #JDRF#Immunology #ClinicalResearch #Endocrinology #AutoimmuneDisease #MedicalInnovation #BetaCells #T1D #HealthcareInnovation #ClinicalTrials sab.bio Download the transcript here

Marcus Ionker, Product Line Manager and Messaging Evangelist at Retarus, which is a cloud-based transactional electronic messaging service provider offering fax, SMS, email, and logistics services to regulated industries like healthcare. By moving fax to the cloud, Retarus helps providers and payers reduce administrative costs, improve patient services, and comply with privacy regulations. The company is addressing the critical challenge of providing reliable, secure, and fast messaging to replace outdated physical fax machines and to eliminate paper-based processes in favor of digital workflows.  Marcus explains, "So Retarus is a cloud service provider of what I like to call transactional electronic messaging. So we are talking about fax services, SMS services, email services, as well as even further logistics services. And we do this in many countries, especially in the United States. And a number of those messaging services really play an important role in regulated industries, especially in the healthcare industry, for example." "Email is just not accepted in many of these industries, and that's why fax is still there. And if I may take this opportunity, I think if you do faxing right and if you do it digitally, it makes no difference. It can be an enabler of automated processes, rather than a hindrance." "The paper that we use in the office is when people print emails, not faxes. So no, definitely not. I mean, also, let's keep in mind, a lot of these customers that we offer our service for, they're sending millions and millions of pages every month, and there's no way that you could do that in paper form. So it's coming from an application in a digital form, and quite often on the recipient side is consumed as a digital document, as a PDF or a TIF image, and maybe fed into an AI IDP process immediately. So no, paper often doesn't play a part in this at all." #Retarus #Digitaltransformation #HealthcareCommunications #HealthcareIT #DigitalHealth #CloudFax #HealthcareLeadership #HealthcareInnovation #AdminEfficiency #HealthcareOperations retarus.com  Listen to the podcast here

Marcus Ionker, Product Line Manager and Messaging Evangelist at Retarus, which is a cloud-based transactional electronic messaging service provider offering fax, SMS, email, and logistics services to regulated industries like healthcare. By moving fax to the cloud, Retarus helps providers and payers reduce administrative costs, improve patient services, and comply with privacy regulations. The company is addressing the critical challenge of providing reliable, secure, and fast messaging to replace outdated physical fax machines and to eliminate paper-based processes in favor of digital workflows.  Marcus explains, "So Retarus is a cloud service provider of what I like to call transactional electronic messaging. So we are talking about fax services, SMS services, email services, as well as even further logistics services. And we do this in many countries, especially in the United States. And a number of those messaging services really play an important role in regulated industries, especially in the healthcare industry, for example." "Email is just not accepted in many of these industries, and that's why fax is still there. And if I may take this opportunity, I think if you do faxing right and if you do it digitally, it makes no difference. It can be an enabler of automated processes, rather than a hindrance." "The paper that we use in the office is when people print emails, not faxes. So no, definitely not. I mean, also, let's keep in mind, a lot of these customers that we offer our service for, they're sending millions and millions of pages every month, and there's no way that you could do that in paper form. So it's coming from an application in a digital form, and quite often on the recipient side is consumed as a digital document, as a PDF or a TIF image, and maybe fed into an AI IDP process immediately. So no, paper often doesn't play a part in this at all." #Retarus #Digitaltransformation #HealthcareCommunications #HealthcareIT #DigitalHealth #CloudFax #HealthcareLeadership #HealthcareInnovation #AdminEfficiency #HealthcareOperations retarus.com Download the transcript here

Andrew Hall, CEO of Consano Bio, is developing an allogeneic approach to treat chronic sciatica by activating healing in damaged spinal nerves, emulating the natural healing properties of human platelets.  This condition currently has no approved treatments and is managed through symptomatic approaches like opioids, muscle relaxers, or surgery. Consano Bio's lead candidate represents the first potential disease-modifying therapy for pain management and can be manufactured at scale to treat the estimated 10 million Americans affected by this condition. Andrew explains, "We are developing a potentially disease-modifying treatment that would be given locally for orthopedic painful conditions. The concept is that human platelets are wonderful at eliciting healing in a normal physiological setting. Why can't we create a biologic product that, when given locally, emulates that same functionality where the imbalance has gone bad?"   "I'd call this version one of the first generation of platelet- and plasma-derived biologic therapy. So it runs in the same path. It goes to the same regulators, but it's not so much an evolution as it is a parallel path."   "So chronic sciatica, or when you get fancy with medical terminology, chronic lumbosacral radiculopathy, is basically, and we'll try to keep this PG. I'm a bit Australian and tend to get a little fruity with my language. When you do something silly- wake up, twist, lift the weight badly, bend over- you can pretty easily piss off your spinal nerves, which are the small nerves that come out of your spine and then innervate your extremities."  #ConsanoBIo #Sciatica #BackPain #ChronicPaint #PainTreatment #NonOpioids #LumbosacralRadiculopathy #LSR  #ChronicPain #Biotech #ClinicalTrials #PainManagement #Orthobiologics #DrugDevelopment #HealthcareInnovation #Neurology #MedicalResearch consanobio.com Listen to the podcast here

Andrew Hall, CEO of Consano Bio, is developing an allogeneic approach to treat chronic sciatica by activating healing in damaged spinal nerves, emulating the natural healing properties of human platelets.  This condition currently has no approved treatments and is managed through symptomatic approaches like opioids, muscle relaxers, or surgery. Consano Bio's lead candidate represents the first potential disease-modifying therapy for pain management and can be manufactured at scale to treat the estimated 10 million Americans affected by this condition. Andrew explains, "We are developing a potentially disease-modifying treatment that would be given locally for orthopedic painful conditions. The concept is that human platelets are wonderful at eliciting healing in a normal physiological setting. Why can't we create a biologic product that, when given locally, emulates that same functionality where the imbalance has gone bad?"   "I'd call this version one of the first generation of platelet- and plasma-derived biologic therapy. So it runs in the same path. It goes to the same regulators, but it's not so much an evolution as it is a parallel path."   "So chronic sciatica, or when you get fancy with medical terminology, chronic lumbosacral radiculopathy, is basically, and we'll try to keep this PG. I'm a bit Australian and tend to get a little fruity with my language. When you do something silly- wake up, twist, lift the weight badly, bend over- you can pretty easily piss off your spinal nerves, which are the small nerves that come out of your spine and then innervate your extremities."  #ConsanoBIo #Sciatica #BackPain #ChronicPaint #PainTreatment #NonOpioids #LumbosacralRadiculopathy #LSR  #ChronicPain #Biotech #ClinicalTrials #PainManagement #Orthobiologics #DrugDevelopment #HealthcareInnovation #Neurology #MedicalResearch consanobio.com Download the transcript here

Isobel Handler, Senior Director of Product Management at Kontakt.io addresses critical inefficiencies in clinical exam room utilization.  By capturing data about staff-patient interactions and facility usage, the Kontakt.io platform incorporates real-time location data to optimize patient access, reduce waiting time, and improve staff safety. The solution helps healthcare organizations understand their current capacity utilization before investing in new facilities and supports integration of digital tools to include virtual visits and asychronous communication to better serve patients and reduce clinician burnout.    Isobel explains, "Kontakt.io uses real-time location data, often referred to as RTLS, to improve hospital and clinic operations. We'll talk a lot today about our ambulatory use cases focused on patient access. Still, we also have solutions for inpatient flow, length-of-stay reduction, staff safety, asset tracking, and much more that I won't list. But I think what's really exciting about Kontakt.io is you'll see a lot of RTLS companies in the industry who have built solutions that provide really beautiful blue dots on a map. But at Kontakt.io, we see the opportunity to leverage RTLS beyond that blue dot to produce a set of data that's really well trained and tuned to feed AI models. RTLS data is plentiful, it's machine-generated, it's unbiased, and it doesn't require a human being with a clinical license to enter it. So it produces a lot of really useful information for AI models that are solving some of the top health system problems out there today."   "I think it's an environment that's really ripe for some more data to help us understand what's going on in the exam room, as you pointed out. But a shocking statistic is that most exam rooms are only utilized 33% of the time during standard business hours, which feels incredibly low the first time you hear it. But if you think through the logic of how we get to that utilization rate, the performance actually seems quite intuitive." #KontaktIO #IntelligentOrchestration #HospitalOperations #HealthcareAI #PatientAccess #DigitalHealth #HealthcareInnovation #RTLS #AmbulatoryCare #HealthIT #ClinicianBurnout #HealthcareLeadership  Kontakt.io Listen to the podcast here

Isobel Handler, Senior Director of Product Management at Kontakt.io addresses critical inefficiencies in clinical exam room utilization.  By capturing data about staff-patient interactions and facility usage, the Kontakt.io platform incorporates real-time location data to optimize patient access, reduce waiting time, and improve staff safety. The solution helps healthcare organizations understand their current capacity utilization before investing in new facilities and supports integration of digital tools to include virtual visits and asychronous communication to better serve patients and reduce clinician burnout.    Isobel explains, "Kontakt.io uses real-time location data, often referred to as RTLS, to improve hospital and clinic operations. We'll talk a lot today about our ambulatory use cases focused on patient access. Still, we also have solutions for inpatient flow, length-of-stay reduction, staff safety, asset tracking, and much more that I won't list. But I think what's really exciting about Kontakt.io is you'll see a lot of RTLS companies in the industry who have built solutions that provide really beautiful blue dots on a map. But at Kontakt.io, we see the opportunity to leverage RTLS beyond that blue dot to produce a set of data that's really well trained and tuned to feed AI models. RTLS data is plentiful, it's machine-generated, it's unbiased, and it doesn't require a human being with a clinical license to enter it. So it produces a lot of really useful information for AI models that are solving some of the top health system problems out there today."   "I think it's an environment that's really ripe for some more data to help us understand what's going on in the exam room, as you pointed out. But a shocking statistic is that most exam rooms are only utilized 33% of the time during standard business hours, which feels incredibly low the first time you hear it. But if you think through the logic of how we get to that utilization rate, the performance actually seems quite intuitive." #KontaktIO #IntelligentOrchestration #HospitalOperations #HealthcareAI #PatientAccess #DigitalHealth #HealthcareInnovation #RTLS #AmbulatoryCare #HealthIT #ClinicianBurnout #HealthcareLeadership  Kontakt.io Download the transcript here  

Dr. Steffen-Sebastian Bolz, Founder of QanatPharma, emphasizes the critical role of resistance arteries, microscopic blood vessels that regulate blood flow and pressure throughout the body, in maintaining organ function. Due to their size, these resistance arteries have been overlooked but with new lab techniques, QP is discovering how their dysfunction contributes to heart failure, cognitive impairment and strokes. The company's lead candidate is a repurposed drug already approved for cystic fibrosis that shows promise in restoring brain blood flow and cognitive function in heart failure patients. Steffen-Sebastian explains, "So what we would consider resistance arteries is anything between the capillary level, which would be 10 micrometers, up to, let's say, a few hundred micrometers. And 300 micrometers is the thickness of a blonde hair. That's kind of what we're talking about here. And everything else, and what I talk about in function is what I said before: they can change their diameter. They can open up or close, which large arteries can not do. They are stiff as a garden hose. They are conduits with arteries. They are made to conduct blood at the lowest resistance possible, whereas the small resistance arteries are made to change resistance and regulate flow and pressure."   "As I said, these small resistance arteries and capillaries are everywhere. Every organ has them. And if you compromise the function of those resistance arteries, you compromise blood flow to the capillaries, which actually means that the capillaries don't get enough oxygen. They cannot transport CO2 away from the tissues. They don't get enough nutrients and so on, which then leads to functional damage, which is number one." "And if it persists, if the problem persists, it can also lead to structural damage, which we can actually see. You mentioned the heart. The heart can deal with it, and also the brain can deal with reductions in that flow to a certain extent. But if the reduction in blood flow exceeds a certain limit, you get structural damage. And we see that structural damage. And we call them infarctions in the heart, but also in the brain, which is a stroke." #QanatPharma #VascularBiology #MicrovascularHealth #DrugDiscovery #HeartFailure #CognitiveImpairment #BiotechInnovation #PrecisionMedicine #AIinDrugDiscovery#Microvascular #Neurology #DrugRepurposing #Cardiology #MedicalResearch #ClinicalTrials #Hypertension qanatpharma.com Listen to the podcast here

Dr. Steffen-Sebastian Bolz, Founder of QanatPharma, emphasizes the critical role of resistance arteries, microscopic blood vessels that regulate blood flow and pressure throughout the body, in maintaining organ function. Due to their size, these resistance arteries have been overlooked but with new lab techniques, QP is discovering how their dysfunction contributes to heart failure, cognitive impairment and strokes. The company's lead candidate is a repurposed drug already approved for cystic fibrosis that shows promise in restoring brain blood flow and cognitive function in heart failure patients. Steffen-Sebastian explains, "So what we would consider resistance arteries is anything between the capillary level, which would be 10 micrometers, up to, let's say, a few hundred micrometers. And 300 micrometers is the thickness of a blonde hair. That's kind of what we're talking about here. And everything else, and what I talk about in function is what I said before: they can change their diameter. They can open up or close, which large arteries can not do. They are stiff as a garden hose. They are conduits with arteries. They are made to conduct blood at the lowest resistance possible, whereas the small resistance arteries are made to change resistance and regulate flow and pressure."   "As I said, these small resistance arteries and capillaries are everywhere. Every organ has them. And if you compromise the function of those resistance arteries, you compromise blood flow to the capillaries, which actually means that the capillaries don't get enough oxygen. They cannot transport CO2 away from the tissues. They don't get enough nutrients and so on, which then leads to functional damage, which is number one." "And if it persists, if the problem persists, it can also lead to structural damage, which we can actually see. You mentioned the heart. The heart can deal with it, and also the brain can deal with reductions in that flow to a certain extent. But if the reduction in blood flow exceeds a certain limit, you get structural damage. And we see that structural damage. And we call them infarctions in the heart, but also in the brain, which is a stroke." #QanatPharma #VascularBiology #MicrovascularHealth #DrugDiscovery #HeartFailure #CognitiveImpairment #BiotechInnovation #PrecisionMedicine #AIinDrugDiscovery#Microvascular #Neurology #DrugRepurposing #Cardiology #MedicalResearch #ClinicalTrials #Hypertension qanatpharma.com Download the transcript here

Carlos Buesa, CEO of Oryzon Genomics, specializes in developing precision medicine based on epigenetics, the regulatory mechanisms that control gene expression without altering the DNA. A key target is the LSD1 enzyme which regulates cell differentiation and is a factor in acute myeloid leukemia and CNS disorders. LSD1 inhibition addresses a fundamental insight that the same dysregulated epigenetic genes implicated in leukemia also drive various neruopsychiatric and genetic syndromes suggesting a unified mechanistic understanding of diverse diseases.  Carlos explains, "Epigenetics has been the  i specialization of Oryzon for many years already. We were, I mean, founded back in 2000, but in the last 12 years, we started to develop precision medicines for cancer, broad disorders, and CNS diseases based on epigenetics. And epigenetics, as the name suggests, is something that is above genetics. It's another supplementary level of control that our cells or our organisms have to basically adapt to the changing world. So, epigenetics is a very complex system comprised of many, many different proteins which control which genes are switched on or off without changing the underlying DNA sequence. What we have seen over the last few years is that in disease, those control mechanisms can become dysregulated. And importantly, many epigenetic changes are potentially reversible. So, our strategy here is to develop drugs that act on particular enzymes, epigenetic enzymes, controlling those changes and resetting our normal gene programs."   "A beautiful example of that is leukemia, where there is an extraordinarily complex genetic background, and different epigenetic enzymes offer the capacity to modulate and restore the physiological status to delay the disease, basically to modify the basis of oncological progression. But it's not the only one. We know that epigenetics is working on many other diseases in metabolism, in GI, and some others, but we are also focused on neuropsychiatric disorders. So, these are the two focuses of the company using epigenetics." #OryzonGenomics #Epigenetics #Oncology #Hematology #Schizophrenia #AML #CNS #PrecisionMedicine #ClinicalTrials #HealthcareInnovation #Neuroscience #CNSdisorders #AcuteMyeloidLeukemia #SickleCellDisease oryzon.com Listen to the podcast here

Carlos Buesa, CEO of Oryzon Genomics, specializes in developing precision medicine based on epigenetics, the regulatory mechanisms that control gene expression without altering the DNA. A key target is the LSD1 enzyme which regulates cell differentiation and is a factor in acute myeloid leukemia and CNS disorders. LSD1 inhibition addresses a fundamental insight that the same dysregulated epigenetic genes implicated in leukemia also drive various neruopsychiatric and genetic syndromes suggesting a unified mechanistic understanding of diverse diseases.  Carlos explains, "Epigenetics has been the  i specialization of Oryzon for many years already. We were, I mean, founded back in 2000, but in the last 12 years, we started to develop precision medicines for cancer, broad disorders, and CNS diseases based on epigenetics. And epigenetics, as the name suggests, is something that is above genetics. It's another supplementary level of control that our cells or our organisms have to basically adapt to the changing world. So, epigenetics is a very complex system comprised of many, many different proteins which control which genes are switched on or off without changing the underlying DNA sequence. What we have seen over the last few years is that in disease, those control mechanisms can become dysregulated. And importantly, many epigenetic changes are potentially reversible. So, our strategy here is to develop drugs that act on particular enzymes, epigenetic enzymes, controlling those changes and resetting our normal gene programs."   "A beautiful example of that is leukemia, where there is an extraordinarily complex genetic background, and different epigenetic enzymes offer the capacity to modulate and restore the physiological status to delay the disease, basically to modify the basis of oncological progression. But it's not the only one. We know that epigenetics is working on many other diseases in metabolism, in GI, and some others, but we are also focused on neuropsychiatric disorders. So, these are the two focuses of the company using epigenetics." #OryzonGenomics #Epigenetics #Oncology #Hematology #Schizophrenia #AML #CNS #PrecisionMedicine #ClinicalTrials #HealthcareInnovation #Neuroscience #CNSdisorders #AcuteMyeloidLeukemia #SickleCellDisease oryzon.com Download the transcript here

Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a dual biomarker response and better management of side effects. OS Therapies plans to expand its platform technology to other solid tumors with significant unmet needs, including breast,  esophageal, and colorectal cancer.    Paul explains, "What I think is important is that OS Therapies was started for unmet need, not just in the United States, but there are 20,000 patients a year that get osteosarcoma globally. And it's our responsibility to address patients globally. And it is interesting from a regulatory standpoint, as they start to coordinate with each other, that there are routes for us to get approval in the United States through MHRA, through the UK, and through the collaboration with the EU, with a system called Orbis. But we're also still very confident and very encouraged by the progress we've made with the FDA over the last few months."   "And for OS Therapies, we will pivot to other solid tumors. So our primary mission is osteosarcoma, but once we get approval, we'll pivot to other solid tumors that still have a lot of unmet medical need, like breast cancer. There are still 40,000, mostly women, dying each year of breast cancer, esophageal cancer, or colorectal cancer. So if we can encourage other companies to come into this space, we'll not only achieve our primary mission, but we'll also deliver for patients, which is our goal." #OSTherapies #Osteosarcoma #RareDisease #RareCancer #PediatricOncology #RareDiseaseOncology #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #Biomarkers #Oncology #ClinicalTrials #HER2 #CancerResearch #ComparativeOncology#CanineOsteosarcoma ostherapies.com Listen to the podcast here

Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a dual biomarker response and better management of side effects. OS Therapies plans to expand its platform technology to other solid tumors with significant unmet needs, including breast,  esophageal, and colorectal cancer.    Paul explains, "What I think is important is that OS Therapies was started for unmet need, not just in the United States, but there are 20,000 patients a year that get osteosarcoma globally. And it's our responsibility to address patients globally. And it is interesting from a regulatory standpoint, as they start to coordinate with each other, that there are routes for us to get approval in the United States through MHRA, through the UK, and through the collaboration with the EU, with a system called Orbis. But we're also still very confident and very encouraged by the progress we've made with the FDA over the last few months."   "And for OS Therapies, we will pivot to other solid tumors. So our primary mission is osteosarcoma, but once we get approval, we'll pivot to other solid tumors that still have a lot of unmet medical need, like breast cancer. There are still 40,000, mostly women, dying each year of breast cancer, esophageal cancer, or colorectal cancer. So if we can encourage other companies to come into this space, we'll not only achieve our primary mission, but we'll also deliver for patients, which is our goal." #OSTherapies #Osteosarcoma #RareDisease #RareCancer #PediatricOncology #RareDiseaseOncology #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #Biomarkers #Oncology #ClinicalTrials #HER2 #CancerResearch #ComparativeOncology#CanineOsteosarcoma ostherapies.com Download the transcript here

Dejan Nenov is the Founder of Luventix, an AI-powered diagnostic platform that uses machine learning to analyze metabolic data from urine samples to detect multiple diseases and health conditions.  This approach, inspired by the ability of dogs to detect cancer through smell, enables a single non-invasive test to screen for conditions across oncology, neurology, immunology, and other areas at a fraction of the cost of genetic sequencing or blood tests.  The platform has applications in precision medicine, patient stratification for clinical trials, and population-level health screening.     Dejan explains, "The origin story is actually quite fun. One of my two co-founders and I were sitting around his dining table after a day of skiing and watching TV, and we saw dogs smelling urine and sitting down when the urine was from a cancer patient. And so we started thinking, can we reproduce this with technology? And we looked at it and said, "Well, what does the dog's nose do?" And we said, "Well, it's identifying the molecules in the volatiles of the sample, the urine. That looks suspiciously like gas chromatography."   "And then what happens? Well, the dog's brain determines whether the sample is positive or negative. And that's a classifier, a classic classification problem based on a dataset. So we roll back a year or so, and my co-founder Martin did a study to explore whether he could build models to do what the dogs did, but consistently in a mechanistically repeatable fashion."   "We demonstrated that, yes, indeed, based on creating a digital twin of the patient's organism using metabolic data from a urine sample, we're able to train models that can determine whether a disease or condition is present from a urine sample. In the most general case, that's sort of a patient stratification technology." #Luventix #DigitalHealth #PrecisionMedicine #HealthTech #AIinHealthcare #PatientEmpowerment #HealthInnovation #FutureOfHealthcare #DiagnosticInnovation #HealthTechStartup #ConnectedHealth#HealthcareInnovation #AIinHealthcare #Diagnostics #CancerDetection #MedicalAI #ClinicalTrials #Metabolomics #FutureOfMedicine luventix.com  Listen to the podcast here

Dejan Nenov is the Founder of Luventix, an AI-powered diagnostic platform that uses machine learning to analyze metabolic data from urine samples to detect multiple diseases and health conditions.  This approach, inspired by the ability of dogs to detect cancer through smell, enables a single non-invasive test to screen for conditions across oncology, neurology, immunology, and other areas at a fraction of the cost of genetic sequencing or blood tests.  The platform has applications in precision medicine, patient stratification for clinical trials, and population-level health screening.     Dejan explains, "The origin story is actually quite fun. One of my two co-founders and I were sitting around his dining table after a day of skiing and watching TV, and we saw dogs smelling urine and sitting down when the urine was from a cancer patient. And so we started thinking, can we reproduce this with technology? And we looked at it and said, "Well, what does the dog's nose do?" And we said, "Well, it's identifying the molecules in the volatiles of the sample, the urine. That looks suspiciously like gas chromatography."   "And then what happens? Well, the dog's brain determines whether the sample is positive or negative. And that's a classifier, a classic classification problem based on a dataset. So we roll back a year or so, and my co-founder Martin did a study to explore whether he could build models to do what the dogs did, but consistently in a mechanistically repeatable fashion."   "We demonstrated that, yes, indeed, based on creating a digital twin of the patient's organism using metabolic data from a urine sample, we're able to train models that can determine whether a disease or condition is present from a urine sample. In the most general case, that's sort of a patient stratification technology." #Luventix #DigitalHealth #PrecisionMedicine #HealthTech #AIinHealthcare #PatientEmpowerment #HealthInnovation #FutureOfHealthcare #DiagnosticInnovation #HealthTechStartup #ConnectedHealth#HealthcareInnovation #AIinHealthcare #Diagnostics #CancerDetection #MedicalAI #ClinicalTrials #Metabolomics #FutureOfMedicine luventix.com Download the transcript here

Dr. Hansa Bhargava, Chief Clinical Strategy and Innovation Officer at Healio,  discusses the Healio survey of healthcare professionals to understand evolving attitudes toward AI in clinical practice.  While a significant number of clinicians are leaning into AI adoption, significant trust gaps persist regarding accuracy, data privacy and liability concerns. As AI capabilities advance rapidly, healthcare organizations face pressure to adopt these technologies while maintaining rigorous safeguards and establishing clear policies around shadow AI usage and preserving the human-in-the-loop approach. Hansa explains, "Our core mission is really to support and engage doctors and clinicians in the work that they do. To give you a broad viewpoint, there are about two million peer-reviewed publications a year, and doctors, nurses, and clinicians need to stay up to date to deliver the best quality care to patients. And that is sometimes impossible considering the number of hours that they're doing in the clinical setting. So our goal and our vision are to support them by giving them the information right away and sound bites that they can digest quickly and also get to quickly. Because of that vision and mission, we developed Healio AI to make it even faster and more available in a pure format and using good data sources so that they have the information they need for their patients."   "It's almost impossible for anyone to keep up with those changes. They're exponential, as you just said. And yes, that's definitely a concern, but the other concerns are just fundamental issues of accuracy of the AI delivering the right answers, whether it's frontier models or whether it's a model such as developed by Healio. And then also privacy of patients, data privacy, and also legalities in terms of who holds the bag if things go astray." #Healio #HealioAI #DigitalHealth #HealthcareAI #GenAI #MedicalTechnology #HealthcareProfessionals #CME #PointOfCare #MedicalInformation #HealthTech #PhysicianBurnout #ContinuingEducation #HealthcareInnovation #MedicalJournalism #AIinHealthcare Healio.com  Listen to the podcast here

Dr. Hansa Bhargava, Chief Clinical Strategy and Innovation Officer at Healio,  discusses the Healio survey of healthcare professionals to understand evolving attitudes toward AI in clinical practice.  While a significant number of clinicians are leaning into AI adoption, significant trust gaps persist regarding accuracy, data privacy and liability concerns. As AI capabilities advance rapidly, healthcare organizations face pressure to adopt these technologies while maintaining rigorous safeguards and establishing clear policies around shadow AI usage and preserving the human-in-the-loop approach. Hansa explains, "Our core mission is really to support and engage doctors and clinicians in the work that they do. To give you a broad viewpoint, there are about two million peer-reviewed publications a year, and doctors, nurses, and clinicians need to stay up to date to deliver the best quality care to patients. And that is sometimes impossible considering the number of hours that they're doing in the clinical setting. So our goal and our vision are to support them by giving them the information right away and sound bites that they can digest quickly and also get to quickly. Because of that vision and mission, we developed Healio AI to make it even faster and more available in a pure format and using good data sources so that they have the information they need for their patients."   "It's almost impossible for anyone to keep up with those changes. They're exponential, as you just said. And yes, that's definitely a concern, but the other concerns are just fundamental issues of accuracy of the AI delivering the right answers, whether it's frontier models or whether it's a model such as developed by Healio. And then also privacy of patients, data privacy, and also legalities in terms of who holds the bag if things go astray." #Healio #HealioAI #DigitalHealth #HealthcareAI #GenAI #MedicalTechnology #HealthcareProfessionals #CME #PointOfCare #MedicalInformation #HealthTech #PhysicianBurnout #ContinuingEducation #HealthcareInnovation #MedicalJournalism #AIinHealthcare Healio.com  Download the transcript here

Dr. Carl Rothschild, CEO and Founder, and Eddie Brown, COO of Trifecta Light Technologies, discuss the therapeutic applications of red light and near-infrared therapy by bathing the entire body with these specific light wavelengths. The technology has FDA clearance for fat reduction and healing and clinical research indicates efficacy in neurological disorders and musculoskeletal conditions. The devices are user-friendly and have also been shown to support athletes in recovery and the beauty industry for skin health. Dr. Carl explains, "And so what has since subsequently been learned is that this light of both red, and we also use near infrared, which is even more powerful and more healing; what it does is it affects every cell that we can get to in your body. And the more cells we can get to, the better. That's why you want deep-penetrating, medical-grade beds that can penetrate as much as possible to affect as many cells." Eddie elaborates, "With any kind of red light item, usually the bed, the lights, they're FDA registered, which means basically it's an infrared heat source. What we did with our bed, nobody else was able to do this. Not to say that in the future they're not going to, but right now we're kind of ahead of the curve, the only ones who have it. We've had FDA clearance for ours."   #TrifectaLight #RedLightTherapy #Photobiomodulation #MitochondrialHealth #MetabolicHealth #ChronicCare #SportsMedicine #RegenerativeMedicine Trifectalight.com Listen to the podcast here  

Dr. Carl Rothschild, CEO and Founder, and Eddie Brown, COO of Trifecta Light Technologies, discuss the therapeutic applications of red light and near-infrared therapy by bathing the entire body with these specific light wavelengths. The technology has FDA clearance for fat reduction and healing and clinical research indicates efficacy in neurological disorders and musculoskeletal conditions. The devices are user-friendly and have also been shown to support athletes in recovery and the beauty industry for skin health. Dr. Carl explains, "And so what has since subsequently been learned is that this light of both red, and we also use near infrared, which is even more powerful and more healing; what it does is it affects every cell that we can get to in your body. And the more cells we can get to, the better. That's why you want deep-penetrating, medical-grade beds that can penetrate as much as possible to affect as many cells." Eddie elaborates, "With any kind of red light item, usually the bed, the lights, they're FDA registered, which means basically it's an infrared heat source. What we did with our bed, nobody else was able to do this. Not to say that in the future they're not going to, but right now we're kind of ahead of the curve, the only ones who have it. We've had FDA clearance for ours."  #TrifectaLight #RedLightTherapy #Photobiomodulation #MitochondrialHealth #MetabolicHealth #ChronicCare #SportsMedicine #RegenerativeMedicine Trifectalight.com Download the transcript here  

James Sapirstein, CEO of CoCrystal Pharma, is developing a platform of antiviral therapies to treat norovirus, influenza and other viruses.  Norovirus, commonly transmitted on cruise ships and in dormitories, currently lacks effective vaccines or treatments. CoCrystal's oral small-molecule approach aims to treat active infections by reducing viral shedding duration and provide prophylactic prevention using a novel mechanism that targets viral entry points to prevent replication. James explains, "At CoCrystal Pharma, we have a platform of antiviral programs. The first program is for norovirus, and we have another program for influenza A. And then we also have a platform for rhinovirus, which is also many times referred to as the common cold. There's really not much out there."   "Norovirus is commonly known on cruise ships and in dormitories, college dormitories, and really it spreads by touch. That's why, when cruise ships have an outbreak of norovirus, if people haven't washed their hands or they touch an area where someone has touched that area before with active norovirus, they can get infected. And because people touch their faces over a thousand times, literally in a couple of hours, it's easy to transmit the virus."   "But there's also chronic norovirus, which people don't really talk about much because it's mostly in the nursing homes and assisted living areas, where some of these patients really suffer, and they're septic for a very long period of time. And they're not tested to see if they have norovirus because they have so many other health issues that people just aren't tested correctly." "Most antivirals, for the most part, work on the RNA. They cleave off the RNA, or they cleave off the cell membrane so that it doesn't replicate and the virus dies off. For us, it's much more specific. We like to call it a pocket where the virus enters the cell. We design a drug to specifically kill the virus at certain aspects within the virus, and then it doesn't allow it to replicate. And that's the way it's designed." #CoCrystalPharma #Norovirus #Antivirals #DrugDiscovery #InfectiousDiseases cocrystalpharma.com  Listen to the podcast here

James Sapirstein, CEO of CoCrystal Pharma, is developing a platform of antiviral therapies to treat norovirus, influenza and other viruses.  Norovirus, commonly transmitted on cruise ships and in dormitories, currently lacks effective vaccines or treatments. CoCrystal's oral small-molecule approach aims to treat active infections by reducing viral shedding duration and provide prophylactic prevention using a novel mechanism that targets viral entry points to prevent replication. James explains, "At CoCrystal Pharma, we have a platform of antiviral programs. The first program is for norovirus, and we have another program for influenza A. And then we also have a platform for rhinovirus, which is also many times referred to as the common cold. There's really not much out there."   "Norovirus is commonly known on cruise ships and in dormitories, college dormitories, and really it spreads by touch. That's why, when cruise ships have an outbreak of norovirus, if people haven't washed their hands or they touch an area where someone has touched that area before with active norovirus, they can get infected. And because people touch their faces over a thousand times, literally in a couple of hours, it's easy to transmit the virus."   "But there's also chronic norovirus, which people don't really talk about much because it's mostly in the nursing homes and assisted living areas, where some of these patients really suffer, and they're septic for a very long period of time. And they're not tested to see if they have norovirus because they have so many other health issues that people just aren't tested correctly." "Most antivirals, for the most part, work on the RNA. They cleave off the RNA, or they cleave off the cell membrane so that it doesn't replicate and the virus dies off. For us, it's much more specific. We like to call it a pocket where the virus enters the cell. We design a drug to specifically kill the virus at certain aspects within the virus, and then it doesn't allow it to replicate. And that's the way it's designed." #CoCrystalPharma #Norovirus #Antivirals #DrugDiscovery #InfectiousDiseases cocrystalpharma.com Download the transcript here

Dr. Claire Smith, a regional medical officer at SCP Health and a practicing hospitalist in Missouri, highlights how virtual hospitalists are transforming healthcare by providing 24/7 physician collaboration to support onsite teams, particularly in rural hospitals and during patient surges. Implementing telehospitalists can play a critical role in reducing clinician burnout, improving access to physician expertise, and enhancing emergency department efficiency. Integrating telehospitalists into a care model shows potential to reshape workforce demographics and improve the ability to meet unpredictable demands. Claire explains, "So a hospitalist is typically an internal medicine or family medicine-trained physician who focuses the entirety of their career on hospital medicine. So, taking care of hospitalized patients. They are focused on the end-to-end experience of a patient who is hospitalized. So they are integral in the admission from the emergency department, from the time it is determined the patient needs care within the hospital to the time that they are discharged to their next site of care, whether that be home, a skilled nursing facility, etc. So hospitalists do not focus on outpatient medicine. They collaborate with primary care physicians and care for hospitalized patients."   "And what we are seeing is that we are now integrating virtual hospitalists or telehospitalists into workflows to support teams in a variety of situations, including resource shortages or temporary surges in the patient population, so that we can best support the onsite teams and patients."   "What we see is that telehospitalists are being utilized when demands exceed onsite capacities, as well as in those rural situations where resources are more scarce. So a telehospitalist changes the dynamic from really an occasional ad hoc contact with advanced practitioners who may be supporting rural practice hospital medicine to reliable collaboration."  #SCPHealth #Telehospitalist #RuralHealth #HospitalMedicine #Telemedicine #HealthcareInnovation #ClinicianWellbeing #VirtualCare #24x7Coverage #PatientCare scphealth.com Listen to the podcast here  

Dr. Claire Smith, a regional medical officer at SCP Health and a practicing hospitalist in Missouri, highlights how virtual hospitalists are transforming healthcare by providing 24/7 physician collaboration to support onsite teams, particularly in rural hospitals and during patient surges. Implementing telehospitalists can play a critical role in reducing clinician burnout, improving access to physician expertise, and enhancing emergency department efficiency. Integrating telehospitalists into a care model shows potential to reshape workforce demographics and improve the ability to meet unpredictable demands. Claire explains, "So a hospitalist is typically an internal medicine or family medicine-trained physician who focuses the entirety of their career on hospital medicine. So, taking care of hospitalized patients. They are focused on the end-to-end experience of a patient who is hospitalized. So they are integral in the admission from the emergency department, from the time it is determined the patient needs care within the hospital to the time that they are discharged to their next site of care, whether that be home, a skilled nursing facility, etc. So hospitalists do not focus on outpatient medicine. They collaborate with primary care physicians and care for hospitalized patients."   "And what we are seeing is that we are now integrating virtual hospitalists or telehospitalists into workflows to support teams in a variety of situations, including resource shortages or temporary surges in the patient population, so that we can best support the onsite teams and patients."   "What we see is that telehospitalists are being utilized when demands exceed onsite capacities, as well as in those rural situations where resources are more scarce. So a telehospitalist changes the dynamic from really an occasional ad hoc contact with advanced practitioners who may be supporting rural practice hospital medicine to reliable collaboration."  #SCPHealth #Telehospitalist #RuralHealth #HospitalMedicine #Telemedicine #HealthcareInnovation #ClinicianWellbeing #VirtualCare #24x7Coverage #PatientCare scphealth.com Download the transcript here  

Dr. Mark George is the principal psychiatric investigator of Abbott's TRANSCEND study and also a professor of psychiatry at MUSC Health Institute of Psychiatry.  The TRANSCEND study represents a paradigm shift in depression treatment by investigating deep brain stimulation as a potential solution for treatment-resistant depression. This research involves surgically implanting a device that delivers targeted electrical stimulation to specific brain circuits. By reframing depression as a brain disorder rather than a chemical imbalance, this study emphasizes the biological nature of depression, offering an alternative to a condition with limited options. Mark explains, "There are a lot of people, unfortunately, maybe a quarter of the people with depression who lead lives of misery where the medications and talking just don't get them back on their game. And so that's what we call treatment-resistant depression. And that's where I've spent my career trying to come up with new treatments."   "Well, so if the medications aren't working, you can try even more medicines, but the odds go way down. So there's a whole class of things where we actually stimulate the brain to try to, non-invasively and not using a pill, get in and change circuits in the brain. And those have started to really transform the care of treatment-resistant depression. There are several of them that are both non-invasive, and then others that are invasive."  "But the real holy grail would be for us to find the circuit or the spot in the brain and be able to put something there and then fix it. And then there you go, you live your life, and it would not be a pill that you have to take every day. And it would not have systemic side effects like medications. It wouldn't cause weight gain, sexual side effects, those kinds of things. So the real interest in the deep brain stimulation study that Abbott TRANSCEND is: "Could we stick a wire in the area of the brain that's not working right and pass very, very small amounts of electricity and really wake somebody up and get them out of their depression?" #Abbott #DBS #TRANSCENDstudy  #TRD #TreatmentReistantDepression TRANSCEND  Listen to the podcast here

Dr. Mark George is the principal psychiatric investigator of Abbott's TRANSCEND study and also a professor of psychiatry at MUSC Health Institute of Psychiatry.  The TRANSCEND study represents a paradigm shift in depression treatment by investigating deep brain stimulation as a potential solution for treatment-resistant depression. This research involves surgically implanting a device that delivers targeted electrical stimulation to specific brain circuits. By reframing depression as a brain disorder rather than a chemical imbalance, this study emphasizes the biological nature of depression, offering an alternative to a condition with limited options. Mark explains, "There are a lot of people, unfortunately, maybe a quarter of the people with depression who lead lives of misery where the medications and talking just don't get them back on their game. And so that's what we call treatment-resistant depression. And that's where I've spent my career trying to come up with new treatments."   "Well, so if the medications aren't working, you can try even more medicines, but the odds go way down. So there's a whole class of things where we actually stimulate the brain to try to, non-invasively and not using a pill, get in and change circuits in the brain. And those have started to really transform the care of treatment-resistant depression. There are several of them that are both non-invasive, and then others that are invasive."  "But the real holy grail would be for us to find the circuit or the spot in the brain and be able to put something there and then fix it. And then there you go, you live your life, and it would not be a pill that you have to take every day. And it would not have systemic side effects like medications. It wouldn't cause weight gain, sexual side effects, those kinds of things. So the real interest in the deep brain stimulation study that Abbott TRANSCEND is: "Could we stick a wire in the area of the brain that's not working right and pass very, very small amounts of electricity and really wake somebody up and get them out of their depression?" #Abbott #DBS #TRANSCENDstudy  #TRD #TreatmentReistantDepression TRANSCEND  Download the transcript here

Dr. Manish Arora, CEO at LinusBio, has developed an innovative approach to precision medicine through the Traced test, which measures exposure to trace elements and environmental toxins using hair biomarkers. The technology analyzes a small hair sample and can measure chemicals that enter the bloodstream and deposit in the hair as it grows.  This exposome-based test identifies exposure patterns through longitudinal monitoring and provides a precise method to measure environmental impacts, unlike genomic biomarkers, and offers actionable guidance for reducing toxic exposure. Manish explains, "So we like using hair for many reasons. One is we can collect it very easily at home. All you need is a pair of household scissors, a quick snip, and we only ask you for about three to five strands. We don't need a whole lot. What is amazing about hair is that it can actually give you a daily readout over the past month. And let me share with you how this happens. If you've ever seen a tree that's been cut down and you've seen growth rings in it, we think of them as yearly  growth rings."   "And here there's a growth ring forming almost every hour. So in fact, if you were able to take a strand of hair one centimeter, you would get a whole month of readout at an hourly resolution. That's like 800 to a thousand sequential blood tests. And that's what we have figured out. So unlike many other tests that just give you one number, we give you your monthly profile. Again, all from just one centimeter of hair." "The Traced test, as its first offering, is looking at essential elements like zinc and copper, but also the toxic metals that so many of us have heard of and are concerned about, like lead, cadmium, and arsenic. So what it does is it measures 15 different trace elements, the good and the bad, gives you an overall score, but gives you a daily profile over the last month. And there are such interesting patterns that we find. We find people who have high exposures every five to six days. And very often, when we speak to them, they're doing something very different on the weekend, which is a source of exposure. So we keep finding these patterns and instead of just saying, "Hey, you are high or low," we can work with them, look at these patterns, and then give them exposure guidance. Simple steps: how to improve your environment, how to reduce your toxic exposures." #LinusBio #TracedTest #PrecisionMedicine #Exposome #DigitalBiomarkers #EnvironmentalHealth #PreventiveCare #HealthcareInnovation #Diagnostics #Toxins #Wellness #HealthTech #Environment  linusbio.com  Listen to the podcast here

Dr. Manish Arora, CEO at LinusBio, has developed an innovative approach to precision medicine through the Traced test, which measures exposure to trace elements and environmental toxins using hair biomarkers. The technology analyzes a small hair sample and can measure chemicals that enter the bloodstream and deposit in the hair as it grows.  This exposome-based test identifies exposure patterns through longitudinal monitoring and provides a precise method to measure environmental impacts, unlike genomic biomarkers, and offers actionable guidance for reducing toxic exposure. Manish explains, "So we like using hair for many reasons. One is we can collect it very easily at home. All you need is a pair of household scissors, a quick snip, and we only ask you for about three to five strands. We don't need a whole lot. What is amazing about hair is that it can actually give you a daily readout over the past month. And let me share with you how this happens. If you've ever seen a tree that's been cut down and you've seen growth rings in it, we think of them as yearly  growth rings."   "And here there's a growth ring forming almost every hour. So in fact, if you were able to take a strand of hair one centimeter, you would get a whole month of readout at an hourly resolution. That's like 800 to a thousand sequential blood tests. And that's what we have figured out. So unlike many other tests that just give you one number, we give you your monthly profile. Again, all from just one centimeter of hair." "The Traced test, as its first offering, is looking at essential elements like zinc and copper, but also the toxic metals that so many of us have heard of and are concerned about, like lead, cadmium, and arsenic. So what it does is it measures 15 different trace elements, the good and the bad, gives you an overall score, but gives you a daily profile over the last month. And there are such interesting patterns that we find. We find people who have high exposures every five to six days. And very often, when we speak to them, they're doing something very different on the weekend, which is a source of exposure. So we keep finding these patterns and instead of just saying, "Hey, you are high or low," we can work with them, look at these patterns, and then give them exposure guidance. Simple steps: how to improve your environment, how to reduce your toxic exposures." #LinusBio #TracedTest #PrecisionMedicine #Exposome #DigitalBiomarkers #EnvironmentalHealth #PreventiveCare #HealthcareInnovation #Diagnostics #Toxins #Wellness #HealthTech #Environment  linusbio.com Download the transcript here

Xiaoxi Wei, CEO and Co-Founder of X-Therma, is revolutionizing organ transplantation by extending the preservation time of donor organs through advanced biopreservation technology. This approach addresses the gap in organ transplantation that exists because of limitations of cold storage, which constrains the hours of viability of an organ and results in over 50% of donated organs going unused.  By enabling longer preservation times, X-Therma increases organ availability and organ quality, expands geographic access to organs, and enhances donor-recipient matching.    Xiaoxi explains, "X-Therma is trying to make time available for all the patients who are waiting for lifesaving living medicines, such as organs for transplantation, cell and gene therapy for curing cancer, and tissue engineering products for rejuvenating your body parts. So all of those so-called living medicines with the current technology, they do not have a way to be put off the shelf, but we are changing that. At X-Therma, we firmly believe biological time is no longer fixed. So by advancing safe biopreservation, we make them last for an unprecedented amount of time. So those lifesaving organs can be off the shelf.  For example, at the organ site, we do about 27,000 kidney transplants per year, and roughly 100,000 patients are waiting on the official waiting list." "But actually, the real reason we have such a gap is not that we don't have enough organs - 60% of us are willing to donate organs to save others' lives. The biggest issue here is that we cannot keep those organs alive for more than 24 hours at a time. So, long story short, we're changing this time from less than a day to days for lifesaving organs. So you will have time, and then we can increase the organ volume for transplants and save more patients from waiting." #XTherma #TransplantInnovation #OrganPreservation #KidneyTransplant #HealthcareInnovation #Surgery #Nephrology #Biotech #PatientOutcomes x-therma.com Listen to the podcast here